Natixis Advisors LLC Grows Stake in Koninklijke Philips (NYSE:PHG)

Natixis Advisors LLC raised its stake in Koninklijke Philips (NYSE:PHG) by 3.7% during the 4th quarter, HoldingsChannel reports. The firm owned 741,277 shares of the technology company’s stock after acquiring an additional 26,227 shares during the quarter. Natixis Advisors LLC’s holdings in Koninklijke Philips were worth $18,769,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in PHG. PNC Financial Services Group Inc. raised its position in Koninklijke Philips by 4.8% in the third quarter. PNC Financial Services Group Inc. now owns 36,291 shares of the technology company’s stock valued at $1,187,000 after purchasing an additional 1,676 shares during the period. West Family Investments Inc. acquired a new stake in shares of Koninklijke Philips during the third quarter valued at about $252,000. Charles Schwab Investment Management Inc. grew its stake in shares of Koninklijke Philips by 26.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 55,290 shares of the technology company’s stock valued at $1,809,000 after acquiring an additional 11,538 shares in the last quarter. Cerity Partners LLC grew its stake in shares of Koninklijke Philips by 16.8% during the third quarter. Cerity Partners LLC now owns 60,112 shares of the technology company’s stock valued at $1,967,000 after acquiring an additional 8,625 shares in the last quarter. Finally, Pitcairn Co. acquired a new stake in shares of Koninklijke Philips during the third quarter valued at about $256,000. 13.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. UBS Group upgraded Koninklijke Philips from a “neutral” rating to a “buy” rating in a research note on Thursday, February 20th. StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. Finally, BNP Paribas upgraded Koninklijke Philips from a “neutral” rating to an “outperform” rating in a research note on Tuesday, February 25th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Koninklijke Philips Stock Down 2.0 %

NYSE:PHG opened at $26.30 on Wednesday. The company has a market capitalization of $24.72 billion, a price-to-earnings ratio of -31.30, a price-to-earnings-growth ratio of 0.82 and a beta of 0.78. Koninklijke Philips has a one year low of $19.10 and a one year high of $32.91. The stock has a 50-day simple moving average of $26.70 and a 200 day simple moving average of $27.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.74 and a current ratio of 1.23.

Koninklijke Philips (NYSE:PHG) last posted its quarterly earnings results on Wednesday, February 19th. The technology company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.01). The firm had revenue of $5.38 billion during the quarter, compared to analyst estimates of $5.10 billion. Koninklijke Philips had a positive return on equity of 10.85% and a negative net margin of 3.88%. Sell-side analysts predict that Koninklijke Philips will post 1.63 EPS for the current fiscal year.

Koninklijke Philips Cuts Dividend

The company also recently declared an annual dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 13th will be paid a $0.886 dividend. The ex-dividend date of this dividend is Tuesday, May 13th. This represents a yield of 2.9%. Koninklijke Philips’s dividend payout ratio (DPR) is -89.29%.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.